Treatment of autosomal recessive congenital ichthyosis caused by a <i>NIPAL4</i> variant with upadacitinib-Reference-Cited by-同舟云学术

Treatment of autosomal recessive congenital ichthyosis caused by a NIPAL4 variant with upadacitinib

Published:2024-05-29 Issue: Volume: Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Gong Zhuoqing¹²,Wang Yu¹^ORCID,Jiang Xingyuan²^ORCID,Wang Huijun¹,Lin Zhimiao¹^ORCID

Affiliation:

1. Dermatology Hospital Southern Medical University Guangzhou China

2. Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Department of Dermatology, National Clinical Research Center for Skin and Immune Diseases Peking University First Hospital Beijing China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.20130

Reference10 articles.

1. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

2. Expanding the clinical phenotype associated with NIPAL4 mutation: Study of a Tunisian consanguineous family with erythrokeratodermia variabilis—Like Autosomal Recessive Congenital Ichthyosis

3. Congenital ichthyosis: a practical clinical guide on current treatments and future perspectives;Lilly E;Clin Cosmet Investig Dermatol,2023

4. Expanding the molecular and clinical spectrum of autosomal recessive congenital ichthyosis caused by pathogenic variants in NIPAL4 and PNPLA1 and evaluation of novel therapeutic interventions

5. Tofacitinib reduces skin inflammation in a patient with severe autosomal recessive congenital ichthyosis;Lin Y;J Invest Dermatol,2023